GlassScriptImbrium Therapeutics L.P.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Philip Hanno | Stanford, CA | Urology | $16,896.00 |
| Glen Apseloff | Columbus, OH | $9,715.00 | |
| Raymond Anton | Charleston, SC | Addiction Psychiatry | $9,054.00 |
| Roger Dmochowski | Nashville, TN | Urology | $7,175.00 |
| Anita Dsouza | Milwaukee, WI | Hematology & Oncology | $6,558.02 |
| Paul Hamlin | New York, NY | Medical Oncology | $5,841.50 |
| Pamela Allen | Atlanta, GA | Hematology & Oncology | $5,652.61 |
| Eric Jacobsen | Boston, MA | Hematology & Oncology | $5,594.20 |
| Qaiser Bashir | Houston, TX | Hematology & Oncology | $5,567.50 |
| Amitkumar Mehta | Birmingham, AL | Hematology & Oncology | $5,567.50 |
Share this page
The CSV has this whole record: yearly general payments, research totals, product associations, the specialty mix, and the largest reported clinician totals.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.